about
Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicantsKidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.Recommendations for the evaluation of pathology data in nonclinical safety biomarker qualification studies.Regulatory Forum Opinion Piece*: Imaging Applications in Toxicologic Pathology-Recommendations for Use in Regulated Nonclinical Toxicity Studies.A rapid urine test for early detection of kidney injury.Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.In vivo CXCR4 expression, lymphoid cell phenotype, and feline immunodeficiency virus infection.Rat Urinary Osteopontin and Neutrophil Gelatinase-Associated Lipocalin Improve Certainty of Detecting Drug-Induced Kidney Injury.Graphical display of histopathology data from toxicology studies for drug discovery and development: An industry perspective.Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing ConsortiumTowards consensus practices to qualify safety biomarkers for use in early drug developmentTopic of histopathology blinding in nonclinical safety biomarker qualification studiesEvaluation of the relative performance of 12 urinary biomarkers for renal safety across 22 rat sensitivity and specificity studiesPerformance Assessment of New Urinary Translational Safety Biomarkers of Drug-induced Renal Tubular Injury in Tenofovir-treated Cynomolgus Monkeys and Beagle DogsScientific and Regulatory Policy Committee Points to Consider: Data Visualization for Clinical and Anatomic PathologistsScientific and Regulatory Policy Committee Points to Consider*: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic PathologistsScientific and Regulatory Policy Committee Points to Consider*: The Toxicologic Pathologist's Role in the 3RsToxicologic Pathology Forum*: Commentary on "Opinion on Designation of Adverse and Nonadverse Histopathological Findings in Toxicity Studies: The Pathologist's Dilemma"Kidney Safety Assessment: Current Practices in Drug DevelopmentTranslational Safety Biomarkers of Kidney InjuryrVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
P50
Q28578556-66D12410-E364-4A63-9CDB-89203E68381FQ33913977-A2D559FA-C32D-4CF3-875E-19F6707DD697Q34083600-2CA8C7D7-7BD8-49DB-9EFE-0A439BFFC411Q36412738-5403B412-00F7-4029-AF8C-FC1DBDBB8A30Q37331901-EF8BAB8F-411C-42D8-84E3-F5370354B4D0Q38375013-437C789D-CA3C-40DB-8DFF-2C37F5DF3E09Q39038623-8A4150E1-77A4-48EB-8E41-7C01FD554BF7Q39878923-2673F3F3-D73F-4AA4-95C7-B732EE5365D1Q52869498-759C82DD-F8EA-4F8E-9141-ECD45377B22AQ58071225-08859FE9-BB2C-4D3C-B5F5-D0D8663B8D6EQ58071230-48CE8E42-76CC-401A-AE38-53F8109E07E4Q84368750-B33F310C-E22C-4B4C-984B-28D2D4261F21Q86991580-A190336A-9BC7-4E8B-9F65-AFA2C990060BQ88883655-10166670-570D-4CD7-ABB0-71726BB65292Q88907930-559E81BB-D3BD-49FD-B862-2C15BC84FB52Q90595191-38B3F405-98BF-4517-9D0C-7604F99DA395Q90926648-04CB7600-3DB7-4E7D-AD75-53FD5F25858FQ91860480-AAC7EF13-1BC8-4887-BA42-5F3A29C6E34DQ92081169-619BC9B2-552D-444D-ABD0-DCB550A58271Q92081210-4807DD4B-E1E7-482F-A644-13BE587CB69FQ92437405-A5352FAA-0CBE-4777-B851-6E94AAB274AD
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Sean P Troth
@en
Sean P Troth
@nl
type
label
Sean P Troth
@en
Sean P Troth
@nl
prefLabel
Sean P Troth
@en
Sean P Troth
@nl
P31
P496
0000-0002-4696-5129